Pre-clinical development of a combination microbicide vaginal ring containing dapivirine and darunavir

Diarmaid J. Murphy, Delphine Desjardins, Nathalie Dereuddre-Bosquet, Patricia Brochard, Ludivine Perrot, Alain Pruvost, Roger Le Grand, Ole Lagatie, Leen Vanhooren, Maxim Feyaerts, Jens van Roey, R. Karl Malcolm

Research output: Contribution to journalArticlepeer-review

35 Citations (Scopus)
25 Downloads (Pure)

Abstract

Objectives: Combination microbicide vaginal rings may be more effective than single microbicide rings at reducing/preventing sexual transmission of HIV. Here, we report the preclinical development and macaque pharmacokinetics of matrix-type silicone elastomer vaginal rings containing dapivirine and darunavir.

Methods: Macaque rings containing 25 mg dapivirine, 300 mg darunavir and 100 mg dapivirine, and 300 mg darunavir were manufactured and characterised by differential scanning calorimetry. In vitro release was assessed into isopropanol/water and simulated vaginal fluid. Macaque vaginal fluid and blood serum concentrations for both antiretrovirals were measured during 28-day ring use. Tissue levels were measured on day 28. Ex vivo challenge studies were performed on vaginal fluid samples and IC50 values calculated.

Results: Darunavir caused a concentration-dependent reduction in the dapivirine melting temperature in both solid drug mixes and in the combination ring. In vitro release from rings was dependent on drug loading, the number of drugs present, and the release medium. In macaques, serum concentrations of both microbicides were maintained between 101–102 pg/mL. Vaginal fluid levels ranged between 103–104 ng/g and 104–105 ng/g for dapivirine and darunavir, respectively. Tissue concentrations ranges for each drug were: vagina (1.8×103–3.8×103 ng/g) > cervix (9.4×101–3.9×102 ng/g) > uterus (0–108 ng/g) > rectum (0–40 ng/g). Measured IC50 values were > 2 ng/mL for both compounds.

Conclusions: Based on these results, and in light of recent clinical progress of the 25mg dapivirine ring, a combination vaginal ring containing dapivirine and darunavir is a viable second-generation HIV microbicide candidate.
Original languageEnglish
Pages (from-to)2477-2488
Number of pages12
JournalJournal of Antimicrobial Chemotherapy
Volume69
Issue number9
DOIs
Publication statusPublished - Sep 2014

Keywords

  • HIV microbicide; Silicone elastomer vaginal ring; Cynomolgus macaque; Pharmacokinetics

Fingerprint

Dive into the research topics of 'Pre-clinical development of a combination microbicide vaginal ring containing dapivirine and darunavir'. Together they form a unique fingerprint.

Cite this